-
公开(公告)号：US09012417B2
公开(公告)日：2015-04-21
申请号：US10468717
申请日：2002-02-06
IPC分类号： A61K48/00 , A61K31/711 , A61K38/17 , C12N15/113
CPC分类号： A61K31/711 , A61K38/1709 , C12N15/113 , C12N2310/13
摘要： A pharmaceutical composition for performing treatment against a skin disease, the pharmaceutical composition comprising at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy may be selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The at least one decoy may be an oligonucleotide including at least two decoys bonded to each other, the at least two decoys being selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The skin disease may be atopic dermatitis, psoriasis vulgaris, contact dermatitis, keloid, bedsore, ulcerative colitis, or Crohn's disease.
摘要翻译： 一种用于对皮肤病进行治疗的药物组合物，所述药物组合物包含至少一种诱饵和药学上可接受的载体。 所述至少一个诱饵可以选自NF-和kgr B诱饵，STAT-1诱饵，GATA-3诱饵，STAT-6诱饵，AP-1诱饵和Ets诱饵。 所述至少一个诱饵可以是包含至少两个彼此键合的诱饵的寡核苷酸，所述至少两个诱饵选自由NF-和κB诱饵，STAT-1诱饵，GATA-3诱饵 ，STAT-6诱饵，AP-1诱饵和Ets诱饵。 皮肤病可能是特应性皮炎，寻常型牛皮癣，接触性皮炎，瘢痕疙瘩，褥疮，溃疡性结肠炎或克罗恩病。
-
2.发明授权Circular dumbbell decoy oligodeoxynucleotides (CDODN) containing DNA bindings sites of transcription 有权圆形哑铃诱饵寡脱氧核苷酸（CDODN）含有DNA结合位点的转录公开(公告)号：US08647820B2
公开(公告)日：2014-02-11
申请号：US13036578
申请日：2011-02-28
申请人： In-Kyu Lee , Ryuichi Morishita
发明人： In-Kyu Lee , Ryuichi Morishita
CPC分类号： C12N15/113 , A61K38/00 , C12N2310/13 , C12N2310/53
摘要： The present invention provides a circular dumbbell oligodeoxynucleotide (CDODN) comprising two loop structures and a stem structure, wherein the stem structure comprises a nucleotide sequence capable of binding the DNA-binding domain of a transcriptional factor. The present invention further provides a pharmaceutical composition comprising said CDODN. The pharmaceutical composition can be used for treating and/or preventing a disease or disorder related to such a transcriptional factor. The present invention also provides a method for treating and/or preventing a disease or disorder related to such a transcriptional factor, comprising administering to the subject a therapeutically effective amount of a CDODN comprising two loop structures and a stem structure, wherein the stem structure comprises a nucleotide sequence capable of binding the DNA-binding domain of the transcriptional factor.
摘要翻译： 本发明提供了包含两个环结构和茎结构的环状哑铃寡脱氧核苷酸（CDODN），其中所述茎结构包含能够结合转录因子的DNA结合结构域的核苷酸序列。 本发明还提供了包含所述CDODN的药物组合物。 药物组合物可用于治疗和/或预防与这种转录因子相关的疾病或病症。 本发明还提供了用于治疗和/或预防与这种转录因子相关的疾病或病症的方法，包括向受试者施用治疗有效量的包含两个环结构和茎结构的CDODN，其中茎结构包括 能够结合转录因子的DNA结合结构域的核苷酸序列。
-
公开(公告)号：US20120052104A1
公开(公告)日：2012-03-01
申请号：US13254843
申请日：2010-03-05
申请人： Takefumi Gemba , Hideki Tomioka , Nao Tamura , Akiko Tenma
发明人： Takefumi Gemba , Hideki Tomioka , Nao Tamura , Akiko Tenma
IPC分类号： A01N25/34 , C07K14/00 , A01N37/18 , A01P3/00 , A61P1/00 , A61P17/00 , A61K38/10 , A61P9/10 , A61P31/04 , A61P31/10 , A61P17/02 , C07K7/08 , A61K38/16
CPC分类号： A61L15/46 , A61K38/00 , A61L2300/25 , A61L2300/404 , C07K7/08 , C07K14/212
摘要： A novel polypeptide, and an antibacterial agent, antifungal agent and/or antiseptic containing as an effective ingredient the polypeptide are disclosed. The polypeptide of this invention has an amino acid sequence shown in SEQ ID NOs:1 to 12 and 13 to 31. This antibacterial agent, antifungal agent and/or antiseptic is useful for the prevention, amelioration or treatment of diseases such as burn, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliterans, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, skin abscess, necrotizing subcutaneous infection, staphylococcal scalded skin syndrome (SSSS), folliculitis, facial furuncle, suppurative hidradenitis, carbuncle, infectious paronychia, erythrasma and severe infection (sepsis).
摘要翻译： 公开了一种新颖的多肽，以及含有该多肽的有效成分的抗菌剂，抗真菌剂和/或防腐剂。 本发明的多肽具有SEQ ID NO：1至12和13至31所示的氨基酸序列。该抗菌剂，抗真菌剂和/或防腐剂可用于预防，改善或治疗诸如烧伤，褥疮 伤口，皮肤溃疡，腿部溃疡，糖尿病性溃疡，闭塞性动脉疾病和闭塞性闭塞性动脉硬化症，蜂窝织炎，急性淋巴管炎，淋巴结炎，丹毒，皮肤脓肿，坏死性皮下感染，葡萄球菌性烫伤皮肤综合征（SSSS），毛囊炎，面部le疮，化脓性头痛 ，carb，感染性甲沟炎，红斑狼疮和严重感染（败血症）。
-
公开(公告)号：US07595301B2
公开(公告)日：2009-09-29
申请号：US10568226
申请日：2004-09-29
CPC分类号： A61K31/713 , C12N15/111 , C12N2310/11 , C12N2310/14 , C12N2310/53 , C12N2320/51
摘要： Conventional oligonucleotides are opened at both ends and thereby unstable. Their stability against catabolic enzymes is increased by phosphorothioate modification, but such phosphorothioate causes toxicity. The present invention provides oligonucleotides and medicaments in which these problems are improved. That is, it provides staple oligonucleotides and medicaments containing the same as the active ingredient. Specifically, it provides transcription factor inhibitors, antisense oligonucleotides and siRNAs. More specifically, it provides agents for preventing, treating or improving inflammation, autoimmune diseases, central diseases, reperfusion injury in ischaemic diseases, worsened prognosis after organ transplantation or organ surgery, or restenosis after PTCA. Further specifically, it provides agents for preventing, treating or improving arthritis, dermatitis, nephritis, hepatitis, renal failure, cystitis, prostatitis, urethritis, ulcerative colitis, Crohn disease, chronic rheumatoid arthritis, osteoarthritis, atopic dermatitis, contact dermatitis, psoriasis, cutaneous ulcer or decubitus.
摘要翻译： 常规寡核苷酸在两端开放，从而不稳定。 它们对分解代谢酶的稳定性通过硫代磷酸酯修饰而增加，但是这种硫代磷酸酯会引起毒性。 本发明提供了改善这些问题的寡核苷酸和药物。 也就是说，它提供含有与活性成分相同的主要寡核苷酸和药物。 具体来说，它提供转录因子抑制剂，反义寡核苷酸和siRNA。 更具体地说，它提供用于预防，治疗或改善炎症，自身免疫性疾病，中枢性疾病，缺血性疾病中的再灌注损伤，器官移植或器官手术后的预后恶化或PTCA后的再狭窄的药剂。 更具体地说，它提供预防，治疗或改善关节炎，皮炎，肾炎，肝炎，肾衰竭，膀胱炎，前列腺炎，尿道炎，溃疡性结肠炎，克罗恩病，慢性类风湿性关节炎，骨关节炎，特应性皮炎，接触性皮炎，牛皮癣，皮肤 溃疡或褥疮。
-
5.发明申请公开(公告)号：US20090105183A1
公开(公告)日：2009-04-23
申请号：US12314009
申请日：2008-12-02
IPC分类号： A61K31/7088 , A61P17/00
CPC分类号： A61K31/711 , A61K38/1709 , C12N15/113 , C12N2310/13
摘要： A pharmaceutical composition for performing treatment against a skin disease, the pharmaceutical composition comprising at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy may be selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The at least one decoy may be an oligonucleotide including at least two decoys bonded to each other, the at least two decoys being selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The skin disease may be atopic dermatitis, psoriasis vulgaris, contact dermatitis, keloid, bedsore, ulcerative colitis, or Crohn's disease.
摘要翻译： 一种用于对皮肤病进行治疗的药物组合物，所述药物组合物包含至少一种诱饵和药学上可接受的载体。 所述至少一个诱饵可以选自NF-κB诱饵，STAT-1诱饵，GATA-3诱饵，STAT-6诱饵，AP-1诱饵和Ets诱饵。 所述至少一个诱饵可以是包含至少两个彼此键合的诱饵的寡核苷酸，所述至少两个诱饵选自NF-κB诱饵，STAT-1诱饵，GATA-3诱饵， STAT-6诱饵，AP-1诱饵和Ets诱饵。 皮肤病可能是特应性皮炎，寻常型牛皮癣，接触性皮炎，瘢痕疙瘩，褥疮，溃疡性结肠炎或克罗恩病。
-
公开(公告)号：US20090082263A1
公开(公告)日：2009-03-26
申请号：US11658897
申请日：2005-07-29
IPC分类号： A61K38/18 , A61K31/7088 , C07K14/475
CPC分类号： A61K38/1858 , A01K67/027 , A61K38/1825 , A61K38/1833 , A61K48/00
摘要： It is intended to provide a novel remedy for improving the brain function or preventing the same from worsening and a novel administration method for the remedy. Namely, a composition for preventing the brain function from worsening or improving the brain function which contains a cell growth factor. It is preferred that this cell growth factor is one selected from the group consisting of vascular endothelial growth factors (VEGFs), fibroblast growth factors (FGFs) and hepatocyte growth factors (HGFs). A method for preventing the brain function from worsening or improving the brain function which comprises the step of administering a cell growth factor to a patient.
摘要翻译： 旨在提供改善脑功能或防止其相同恶化的新颖的治疗方法以及用于治疗的新型治疗方法。 即，用于防止脑功能恶化或改善包含细胞生长因子的脑功能的组合物。 优选该细胞生长因子是选自血管内皮生长因子（VEGF），成纤维细胞生长因子（FGF）和肝细胞生长因子（HGF））中的一种。 一种防止脑功能恶化或改善脑功能的方法，包括向患者施用细胞生长因子的步骤。
-
公开(公告)号：US07285540B2
公开(公告)日：2007-10-23
申请号：US10615292
申请日：2003-07-09
CPC分类号： A61K9/1271 , A61K9/1272 , A61K38/1833 , A61K48/00
摘要： The present invention relates to a medicament comprising a HGF gene. The medicament of the present invention may be topically applied to the target organs so that the effects can be selectively exhibited, resulting in minimizing the side effects of HGF.
摘要翻译： 本发明涉及包含HGF基因的药物。 本发明的药物可以局部施用于靶器官，从而可以选择性地显示效果，从而最小化HGF的副作用。
-
公开(公告)号：US07279333B2
公开(公告)日：2007-10-09
申请号：US10824757
申请日：2004-04-14
申请人： Yasufumi Kaneda
发明人： Yasufumi Kaneda
IPC分类号： C12N15/00
CPC分类号： C12N7/00 , A61K48/00 , C12N15/87 , C12N15/88 , C12N2710/16663 , C12N2760/18823 , C12N2760/18861 , C12N2760/18863
摘要： A gene transfer vector is prepared by introducing an exogenous gene into an inactivated virus envelope, through a freezing and thawing treatment or mixing with a detergent. There are also provided a pharmaceutical composition for gene therapy containing this gene transfer vector, a kit containing this gene transfer vector, and a gene transfer method employing this gene transfer vector.
摘要翻译： 通过冷冻和解冻处理或与洗涤剂混合将外源基因导入灭活的病毒包膜中制备基因转移载体。 还提供了含有该基因转移载体的基因治疗药物组合物，含该基因转移载体的试剂盒和使用该基因转移载体的基因转移方法。
-
9.发明申请Compositions and methods for inhibiting inflammation of vessel walls and formation of neointimal hyperplasia 审中-公开用于抑制血管壁炎症和新内膜增生形成的组合物和方法公开(公告)号：US20060234969A1
公开(公告)日：2006-10-19
申请号：US10548369
申请日：2004-03-05
申请人： Kensuke Egashira
发明人： Kensuke Egashira
IPC分类号： A61K48/00
CPC分类号： A61K48/005
摘要： Compositions and methods for inhibiting inflammation of vessel wall and/or formation of neointimal hyperplasia by gene therapy using a soluble Flt-1 (sFlt-1) gene, are provided. VEGF has an essential role in the development of neointimal hyperplasia by causing inflammation. sFlt-1 gene transfer to the site of vascular injury blocks Flt-1-mediated VEGF signal transduction, thereby inhibiting early inflammation as well as late neointimal hyperplasia. The present invention is useful for inhibiting or treating inflammation of vessel wall and/or formation of neointimal hyperplasia in a patient with risk of post coronary intervention restenosis, atherosclerosis, arteriosclerosis, or edema.
摘要翻译： 提供了通过使用可溶性Flt-1（sFlt-1）基因的基因治疗来抑制血管壁炎症和/或新生内膜增生形成的组合物和方法。 VEGF通过引起炎症在新生内膜增生的发展中起重要作用。 sFlt-1基因转移到血管损伤部位Flt-1介导的VEGF信号转导，从而抑制早期炎症以及晚期新生内膜增生。 本发明可用于抑制或治疗冠状动脉介入再狭窄，动脉粥样硬化，动脉硬化或水肿风险的患者中血管壁炎症和/或内膜增生形成。
-
10.发明申请公开(公告)号：US20060134078A1
公开(公告)日：2006-06-22
申请号：US10536563
申请日：2003-12-02
申请人： Jouji Kokuzawa , Shinichi Yoshimura , Hideomi Kitajima , Jun Shinoda , Yasuhiko Kaku , Toru Iwama , Ryuichi Morishita , Takahiro Kunisada , Noboru Sakai
发明人： Jouji Kokuzawa , Shinichi Yoshimura , Hideomi Kitajima , Jun Shinoda , Yasuhiko Kaku , Toru Iwama , Ryuichi Morishita , Takahiro Kunisada , Noboru Sakai
CPC分类号： C12N5/0623 , A61K35/12 , C12N2501/11 , C12N2501/115 , C12N2501/12 , C12N2510/00
摘要： A medium containing hepatocyte growth factor (HGF) was shown to induce neurosphere formation. Furthermore, the addition of HGF to a culture medium containing FGF-2, EGF, or both increased both the size and number of newly formed neurospheres. Thus, the present invention relates to a growth medium comprising HGF for culturing neural stem cells and methods for culturing the cells using the culture medium.
摘要翻译： 显示含有肝细胞生长因子（HGF）的培养基诱导神经球形成。 此外，向包含FGF-2，EGF或两者的培养基中加入HGF增加新形成的神经球的大小和数量。 因此，本发明涉及包含用于培养神经干细胞的HGF的生长培养基和使用培养基培养细胞的方法。
-
-
-
-
-
-
-
-
-
搜索结果
65 条记录 (耗时 0.025 秒)
